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The role of pharmacokinetics/pharmacodynamics in setting clinical MIC
breakpoints: the EUCAST approach
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Abstract
Clinical breakpoints are used in clinical microbiology laboratories to categorize microorganisms as clinically susceptible (S), intermediate
(I) or resistant (R) dependent on the quantitative antimicrobial susceptibility as indicated by the MIC value determined in a well-deﬁned
standard test system. The laboratory report, with the designations of S, I or R for each antimicrobial agent, provides guidance to clini-
cians with respect to the potential use of agents in the treatment of patients, and clinical breakpoints should therefore distinguish
between patients that are likely or unlikely to respond to antimicrobial treatment. In Europe, clinical breakpoints are set by the Eur-
opean Committee on Antimicrobial Susceptibility Testing (EUCAST), following a deﬁned procedure. This includes evaluation of efﬁcacy
in experimental settings and clinical studies to derive pharmacodynamic targets such as the fAUC/MIC ratio or %fT > MIC required for
efﬁcacy, the pharmacokinetic properties of the agent, Monte Carlo simulations to estimate exposures of the antimicrobial agent in the
target patient population and commonly used dosing regimens. The probability of target attainment is subsequently determined for a
range of pharmacodynamic targets and the results from the Monte Carlo simulations. The breakpoints derived are subsequently evalu-
ated with respect to the wild-type population of the target microorganisms, speciﬁc resistance mechanisms and other relevant data. In
this paper, we provide an overview of the EUCAST process and considerations for setting pharmacokinetic/pharmacodynamic break-
points. These are the breakpoints that in the EUCAST breakpoint tables are referred to as ‘non-species-related breakpoints’.
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